N2MO has a technology to measure the penetration of compounds that can pass the blood-brain barrier (BBB), using grasshoppers as a model organism. The target customers are companies with drug discovery projects for the central nervous system (CNS), having compounds they want to get into the brain. The N2MO technology measures the penetration of the BBB using grasshopper as a model organism. The dissected grasshopper brain is submerged in a solution of the test substance. After a given time the concentration of the substance in the brain is measured and the penetration through the BBB is calculated.

The major advantage is the use of only small amounts of test substance. It requires amounts you get from a first synthesis. The other advantage is the ethical considerations that limit the use of mammals in drug discovery.